anthonyyazdaniml/CT-ADE-SOC huggingface dataset:
Intervention: 1-Bromo-2-fluoro-4-methoxy-3-nitrobenzene
Trial phase: Phase 1
SMILES: COc1ccc(Br)c(F)c1[N+](=O)[O-]
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 5
Group description: Participants received a single IV infusion of andecaliximab 2.5 mg/kg on Day 1.
Eligibility criteria:
Key Inclusion Criteria:

Male or Female, 18 to 65 years of age
Negative pregnancy test at screening
Documented diagnosis of UC with a minimum disease extent of 15 centimeters (cm) from the anal verge
Mayo Score of at least 3 for the SAD cohort and Mayo Score of at least 6 for the MAD cohorts
Hepatic panel (aspartate aminotransferase [AST], alanine aminotransferase [ALT], total bilirubin, direct bilirubin, alkaline phosphatase, lactate dehydrogenase [LDH] ≤ 2 times the upper limit of the normal range [ULN])
Serum creatinine ≤ 1.5 times the ULN
Hemoglobin ≥ 10 grams per deciliter (g/dL) (both males and females)
Absolute neutrophil count (ANC) ≥ 1.5 x 10^9/L (1,500 milli meters [mm]^3)
Platelets ≥ 100 x 10^9/L.

Key Exclusion Criteria:

Pregnant or lactating females
Exhibit severe UC/ clinically significant active infection
Current use of oral corticosteroids at a dose equivalent to > 20 mg/day of prednisone
Any dose adjustment in oral corticosteroids or oral immunosuppressants (6-MP, Azathioprine), or oral 5-aminosalicylate (5-ASA) compounds within 30 days of Baseline
Use of rectal formulations of 5-ASA compounds or corticosteroids within 2 weeks prior to randomization
Crohn's disease or indeterminate colitis
History of colectomy, partial colectomy, or dysplasia on biopsy
Stool sample positive for Clostridium difficile (C. difficile) toxin, E. coli, Salmonella, Shigella, Campylobacter or Yersinia
Treatment with Infliximab, Adalimumab, Natalizumab, Golimumab, Vedolizumab or Certolizumab within 8 weeks of randomization
Any chronic medical condition (including, but not limited to, cardiac or pulmonary disease) that, in the opinion of the Investigator, would make the individual unsuitable for the study or would prevent compliance with the study protocol.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Intervention: 1-Bromo-2-fluoro-4-methoxy-3-nitrobenzene
Trial phase: Phase 1
SMILES: COc1ccc(Br)c(F)c1[N+](=O)[O-]
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 5
Group description: Participants received a single IV infusion of andecaliximab 5.0 mg/kg on Day 1.
Eligibility criteria:
Key Inclusion Criteria:

Male or Female, 18 to 65 years of age
Negative pregnancy test at screening
Documented diagnosis of UC with a minimum disease extent of 15 centimeters (cm) from the anal verge
Mayo Score of at least 3 for the SAD cohort and Mayo Score of at least 6 for the MAD cohorts
Hepatic panel (aspartate aminotransferase [AST], alanine aminotransferase [ALT], total bilirubin, direct bilirubin, alkaline phosphatase, lactate dehydrogenase [LDH] ≤ 2 times the upper limit of the normal range [ULN])
Serum creatinine ≤ 1.5 times the ULN
Hemoglobin ≥ 10 grams per deciliter (g/dL) (both males and females)
Absolute neutrophil count (ANC) ≥ 1.5 x 10^9/L (1,500 milli meters [mm]^3)
Platelets ≥ 100 x 10^9/L.

Key Exclusion Criteria:

Pregnant or lactating females
Exhibit severe UC/ clinically significant active infection
Current use of oral corticosteroids at a dose equivalent to > 20 mg/day of prednisone
Any dose adjustment in oral corticosteroids or oral immunosuppressants (6-MP, Azathioprine), or oral 5-aminosalicylate (5-ASA) compounds within 30 days of Baseline
Use of rectal formulations of 5-ASA compounds or corticosteroids within 2 weeks prior to randomization
Crohn's disease or indeterminate colitis
History of colectomy, partial colectomy, or dysplasia on biopsy
Stool sample positive for Clostridium difficile (C. difficile) toxin, E. coli, Salmonella, Shigella, Campylobacter or Yersinia
Treatment with Infliximab, Adalimumab, Natalizumab, Golimumab, Vedolizumab or Certolizumab within 8 weeks of randomization
Any chronic medical condition (including, but not limited to, cardiac or pulmonary disease) that, in the opinion of the Investigator, would make the individual unsuitable for the study or would prevent compliance with the study protocol.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Intervention: 1-Bromo-2-fluoro-4-methoxy-3-nitrobenzene
Trial phase: Phase 1
SMILES: COc1ccc(Br)c(F)c1[N+](=O)[O-]
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 8
Group description: Participants received 3 single IV infusions of andecaliximab 1.0 mg/kg on Days 1, 15, and 29.
Eligibility criteria:
Key Inclusion Criteria:

Male or Female, 18 to 65 years of age
Negative pregnancy test at screening
Documented diagnosis of UC with a minimum disease extent of 15 centimeters (cm) from the anal verge
Mayo Score of at least 3 for the SAD cohort and Mayo Score of at least 6 for the MAD cohorts
Hepatic panel (aspartate aminotransferase [AST], alanine aminotransferase [ALT], total bilirubin, direct bilirubin, alkaline phosphatase, lactate dehydrogenase [LDH] ≤ 2 times the upper limit of the normal range [ULN])
Serum creatinine ≤ 1.5 times the ULN
Hemoglobin ≥ 10 grams per deciliter (g/dL) (both males and females)
Absolute neutrophil count (ANC) ≥ 1.5 x 10^9/L (1,500 milli meters [mm]^3)
Platelets ≥ 100 x 10^9/L.

Key Exclusion Criteria:

Pregnant or lactating females
Exhibit severe UC/ clinically significant active infection
Current use of oral corticosteroids at a dose equivalent to > 20 mg/day of prednisone
Any dose adjustment in oral corticosteroids or oral immunosuppressants (6-MP, Azathioprine), or oral 5-aminosalicylate (5-ASA) compounds within 30 days of Baseline
Use of rectal formulations of 5-ASA compounds or corticosteroids within 2 weeks prior to randomization
Crohn's disease or indeterminate colitis
History of colectomy, partial colectomy, or dysplasia on biopsy
Stool sample positive for Clostridium difficile (C. difficile) toxin, E. coli, Salmonella, Shigella, Campylobacter or Yersinia
Treatment with Infliximab, Adalimumab, Natalizumab, Golimumab, Vedolizumab or Certolizumab within 8 weeks of randomization
Any chronic medical condition (including, but not limited to, cardiac or pulmonary disease) that, in the opinion of the Investigator, would make the individual unsuitable for the study or would prevent compliance with the study protocol.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Intervention: 1-Bromo-2-fluoro-4-methoxy-3-nitrobenzene
Trial phase: Phase 1
SMILES: COc1ccc(Br)c(F)c1[N+](=O)[O-]
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 8
Group description: Participants received 3 single IV infusions of andecaliximab 2.5 mg/kg on Days 1, 15, and 29.
Eligibility criteria:
Key Inclusion Criteria:

Male or Female, 18 to 65 years of age
Negative pregnancy test at screening
Documented diagnosis of UC with a minimum disease extent of 15 centimeters (cm) from the anal verge
Mayo Score of at least 3 for the SAD cohort and Mayo Score of at least 6 for the MAD cohorts
Hepatic panel (aspartate aminotransferase [AST], alanine aminotransferase [ALT], total bilirubin, direct bilirubin, alkaline phosphatase, lactate dehydrogenase [LDH] ≤ 2 times the upper limit of the normal range [ULN])
Serum creatinine ≤ 1.5 times the ULN
Hemoglobin ≥ 10 grams per deciliter (g/dL) (both males and females)
Absolute neutrophil count (ANC) ≥ 1.5 x 10^9/L (1,500 milli meters [mm]^3)
Platelets ≥ 100 x 10^9/L.

Key Exclusion Criteria:

Pregnant or lactating females
Exhibit severe UC/ clinically significant active infection
Current use of oral corticosteroids at a dose equivalent to > 20 mg/day of prednisone
Any dose adjustment in oral corticosteroids or oral immunosuppressants (6-MP, Azathioprine), or oral 5-aminosalicylate (5-ASA) compounds within 30 days of Baseline
Use of rectal formulations of 5-ASA compounds or corticosteroids within 2 weeks prior to randomization
Crohn's disease or indeterminate colitis
History of colectomy, partial colectomy, or dysplasia on biopsy
Stool sample positive for Clostridium difficile (C. difficile) toxin, E. coli, Salmonella, Shigella, Campylobacter or Yersinia
Treatment with Infliximab, Adalimumab, Natalizumab, Golimumab, Vedolizumab or Certolizumab within 8 weeks of randomization
Any chronic medical condition (including, but not limited to, cardiac or pulmonary disease) that, in the opinion of the Investigator, would make the individual unsuitable for the study or would prevent compliance with the study protocol.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Intervention: 1-Bromo-2-fluoro-4-methoxy-3-nitrobenzene
Trial phase: Phase 1
SMILES: COc1ccc(Br)c(F)c1[N+](=O)[O-]
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 8
Group description: Participants received 3 single IV infusions of andecaliximab 5.0 mg/kg on Days 1, 15, and 29.
Eligibility criteria:
Key Inclusion Criteria:

Male or Female, 18 to 65 years of age
Negative pregnancy test at screening
Documented diagnosis of UC with a minimum disease extent of 15 centimeters (cm) from the anal verge
Mayo Score of at least 3 for the SAD cohort and Mayo Score of at least 6 for the MAD cohorts
Hepatic panel (aspartate aminotransferase [AST], alanine aminotransferase [ALT], total bilirubin, direct bilirubin, alkaline phosphatase, lactate dehydrogenase [LDH] ≤ 2 times the upper limit of the normal range [ULN])
Serum creatinine ≤ 1.5 times the ULN
Hemoglobin ≥ 10 grams per deciliter (g/dL) (both males and females)
Absolute neutrophil count (ANC) ≥ 1.5 x 10^9/L (1,500 milli meters [mm]^3)
Platelets ≥ 100 x 10^9/L.

Key Exclusion Criteria:

Pregnant or lactating females
Exhibit severe UC/ clinically significant active infection
Current use of oral corticosteroids at a dose equivalent to > 20 mg/day of prednisone
Any dose adjustment in oral corticosteroids or oral immunosuppressants (6-MP, Azathioprine), or oral 5-aminosalicylate (5-ASA) compounds within 30 days of Baseline
Use of rectal formulations of 5-ASA compounds or corticosteroids within 2 weeks prior to randomization
Crohn's disease or indeterminate colitis
History of colectomy, partial colectomy, or dysplasia on biopsy
Stool sample positive for Clostridium difficile (C. difficile) toxin, E. coli, Salmonella, Shigella, Campylobacter or Yersinia
Treatment with Infliximab, Adalimumab, Natalizumab, Golimumab, Vedolizumab or Certolizumab within 8 weeks of randomization
Any chronic medical condition (including, but not limited to, cardiac or pulmonary disease) that, in the opinion of the Investigator, would make the individual unsuitable for the study or would prevent compliance with the study protocol.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Intervention: 1-Bromo-2-fluoro-4-methoxy-3-nitrobenzene
Trial phase: Phase 1
SMILES: COc1ccc(Br)c(F)c1[N+](=O)[O-]
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 10
Group description: Participants received 5 single SC doses of andecaliximab 150 mg on Days 1, 8, 15, 22, and 29.
Eligibility criteria:
Key Inclusion Criteria:

Male or Female, 18 to 65 years of age
Negative pregnancy test at screening
Documented diagnosis of UC with a minimum disease extent of 15 centimeters (cm) from the anal verge
Mayo Score of at least 3 for the SAD cohort and Mayo Score of at least 6 for the MAD cohorts
Hepatic panel (aspartate aminotransferase [AST], alanine aminotransferase [ALT], total bilirubin, direct bilirubin, alkaline phosphatase, lactate dehydrogenase [LDH] ≤ 2 times the upper limit of the normal range [ULN])
Serum creatinine ≤ 1.5 times the ULN
Hemoglobin ≥ 10 grams per deciliter (g/dL) (both males and females)
Absolute neutrophil count (ANC) ≥ 1.5 x 10^9/L (1,500 milli meters [mm]^3)
Platelets ≥ 100 x 10^9/L.

Key Exclusion Criteria:

Pregnant or lactating females
Exhibit severe UC/ clinically significant active infection
Current use of oral corticosteroids at a dose equivalent to > 20 mg/day of prednisone
Any dose adjustment in oral corticosteroids or oral immunosuppressants (6-MP, Azathioprine), or oral 5-aminosalicylate (5-ASA) compounds within 30 days of Baseline
Use of rectal formulations of 5-ASA compounds or corticosteroids within 2 weeks prior to randomization
Crohn's disease or indeterminate colitis
History of colectomy, partial colectomy, or dysplasia on biopsy
Stool sample positive for Clostridium difficile (C. difficile) toxin, E. coli, Salmonella, Shigella, Campylobacter or Yersinia
Treatment with Infliximab, Adalimumab, Natalizumab, Golimumab, Vedolizumab or Certolizumab within 8 weeks of randomization
Any chronic medical condition (including, but not limited to, cardiac or pulmonary disease) that, in the opinion of the Investigator, would make the individual unsuitable for the study or would prevent compliance with the study protocol.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Intervention: Lidocaine and tetracaine
Trial phase: Phase 4
SMILES: CCCCNc1ccc(C(=O)OCCN(C)C)cc1.CCN(CC)CC(=O)Nc1c(C)cccc1C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 30
Group description: Anesthetic Topical Adhesive Synera. For subjects taking interferon beta subcutaneous (Betaseron, Extavia or Rebif) apply one patch 60 minutes prior to each injection (every-other day or three times per week) for two weeks, then 30 minutes prior for two weeks.

For subjects taking glatiramer acetate subcutaneous (Copaxone) apply one patch 60 minutes prior to each injection (daily) for one week and then 30 minutes prior for one week.

Anesthetic Topical Adhesive Synera: For subjects taking interferon beta subcutaneous (Betaseron, Extavia or Rebif) apply one patch 60 minutes prior to each injection (every-other day or three times per week) for two weeks, then 30 minutes prior for two weeks.

For subjects taking glatiramer acetate subcutaneous (Copaxone) apply one patch 60 minutes prior to each injection (daily) for one week and then 30 minutes prior for one week
Eligibility criteria:
Inclusion Criteria:

Confirmed diagnosis of Multiple Sclerosis based on McDonald or Poser criteria (no sub-type restrictions)
Aged >18
Regular use of one of the follow Multiple Sclerosis medication treatments: interferon beta subcutaneous (15 subjects, Betaseron, Extavia or Rebif), or glatiramer acetate subcutaneous (15 subjects, Copaxone).
No change in disease modifying therapy in 60 days.
Mean score of ≥1.0 on Local Injection Site Reaction scale and Mean Pain Upon Injection score ≥4.0 during baseline period.
At least 4 valid diary entries over screening period.
No Multiple Sclerosis exacerbation for 60 days prior to screening.
Written informed consent

Exclusion Criteria:

Females who are breast-feeding, pregnant or have potential to become pregnant during the course of the study (fertile and unwilling/unable to use effective contraceptive measures).
Cognitive deficits that would interfere with the subject's ability to give informed consent or perform study testing.
Concurrent application of any topical medication to treat injection site reactions from screening through final visit.
History of allergy to lidocaine, tetracaine or PABA (para-amino benzoic acid) containing products.
Patients receiving class 1 antiarrhythmic agents (i.e. tocainide, mexiletine)
Any other serious and/or unstable medical condition
Intervention: Evacetrapib
Trial phase: Phase 1
SMILES: Cc1cc(C)c2c(c1)[C@@H](N(Cc1cc(C(F)(F)F)cc(C(F)(F)F)c1)c1nnn(C)n1)CCCN2C[C@H]1CC[C@H](C(=O)O)CC1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 10
Group description: Group 1: 130 mg evacetrapib administered once, orally as a tablet to participants with normal hepatic function
Eligibility criteria:
Inclusion Criteria:

Participants have given written informed consent approved by the ethical review board (ERB) governing the site
Female participants should be of non-childbearing potential
Have a body mass index (BMI) of 18 to 40 kilograms per square meter (kg/m^2)
Healthy participants have normal hepatic function as determined by medical history, physical examination, and other screening procedures
Individuals with hepatic impairment classified as Child-Pugh score A, B, or C (mild, moderate, or severe impairment)

Exclusion Criteria:

Has had esophagus variceal bleeding within 3 months of check-in
Have the need to take medications that may interfere with how the liver removes the drug
Have evidence of cancer in the liver
Consumes excessively large amounts of drinks with caffeine or alcohol
Intervention: Evacetrapib
Trial phase: Phase 1
SMILES: Cc1cc(C)c2c(c1)[C@@H](N(Cc1cc(C(F)(F)F)cc(C(F)(F)F)c1)c1nnn(C)n1)CCCN2C[C@H]1CC[C@H](C(=O)O)CC1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 8
Group description: Group 2: 130 mg evacetrapib administered once, orally as a tablet to participants with mild hepatic impairment
Eligibility criteria:
Inclusion Criteria:

Participants have given written informed consent approved by the ethical review board (ERB) governing the site
Female participants should be of non-childbearing potential
Have a body mass index (BMI) of 18 to 40 kilograms per square meter (kg/m^2)
Healthy participants have normal hepatic function as determined by medical history, physical examination, and other screening procedures
Individuals with hepatic impairment classified as Child-Pugh score A, B, or C (mild, moderate, or severe impairment)

Exclusion Criteria:

Has had esophagus variceal bleeding within 3 months of check-in
Have the need to take medications that may interfere with how the liver removes the drug
Have evidence of cancer in the liver
Consumes excessively large amounts of drinks with caffeine or alcohol
Intervention: Evacetrapib
Trial phase: Phase 1
SMILES: Cc1cc(C)c2c(c1)[C@@H](N(Cc1cc(C(F)(F)F)cc(C(F)(F)F)c1)c1nnn(C)n1)CCCN2C[C@H]1CC[C@H](C(=O)O)CC1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 8
Group description: Group 3: 130 mg evacetrapib administered once, orally, as a tablet to participants with moderate hepatic impairment
Eligibility criteria:
Inclusion Criteria:

Participants have given written informed consent approved by the ethical review board (ERB) governing the site
Female participants should be of non-childbearing potential
Have a body mass index (BMI) of 18 to 40 kilograms per square meter (kg/m^2)
Healthy participants have normal hepatic function as determined by medical history, physical examination, and other screening procedures
Individuals with hepatic impairment classified as Child-Pugh score A, B, or C (mild, moderate, or severe impairment)

Exclusion Criteria:

Has had esophagus variceal bleeding within 3 months of check-in
Have the need to take medications that may interfere with how the liver removes the drug
Have evidence of cancer in the liver
Consumes excessively large amounts of drinks with caffeine or alcohol
Intervention: Evacetrapib
Trial phase: Phase 1
SMILES: Cc1cc(C)c2c(c1)[C@@H](N(Cc1cc(C(F)(F)F)cc(C(F)(F)F)c1)c1nnn(C)n1)CCCN2C[C@H]1CC[C@H](C(=O)O)CC1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 6
Group description: Group 4: 130 mg evacetrapib administered once, orally as a tablet to participants with severe hepatic impairment
Eligibility criteria:
Inclusion Criteria:

Participants have given written informed consent approved by the ethical review board (ERB) governing the site
Female participants should be of non-childbearing potential
Have a body mass index (BMI) of 18 to 40 kilograms per square meter (kg/m^2)
Healthy participants have normal hepatic function as determined by medical history, physical examination, and other screening procedures
Individuals with hepatic impairment classified as Child-Pugh score A, B, or C (mild, moderate, or severe impairment)

Exclusion Criteria:

Has had esophagus variceal bleeding within 3 months of check-in
Have the need to take medications that may interfere with how the liver removes the drug
Have evidence of cancer in the liver
Consumes excessively large amounts of drinks with caffeine or alcohol
Intervention: Dexmedetomidine
Trial phase: Phase 2
ATC code: N05CM18
SMILES: Cc1cccc([C@H](C)c2c[nH]cn2)c1C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 7
Group description: Precedex will be started after randomization/prior to catheterization and will be stopped at the end of the procedure. It will be used for an average of 90 minutes and will be used as a continuous intravenous infusion started at 0.3 mcg/kg/hour. If HR > 80 and BP > 120/70, a full loading dose (1.0 mcg/kg/hour) will be administered over 10 minutes. If HR is 60 - 80 or systolic BP is 90 - 120, or age > 65 years, a reduced loading dose of 0.5 mcg/kg will be given over 10 minutes. If no volume overload history, 500mL of colloid (hespan or albumin) will be bolused with 0.2mg of glycopyrrolate. Every 10 minutes, Precedex will be titrated by 0.1 mcg/kg/hour to achieve and maintain RASS of 0 to -1.

Dexmedetomidine: Precedex will be given to randomized subjects in thi study to evaluate its efficacy in maintaining optimal sedation and preserving neurological exam.
Eligibility criteria:
Inclusion Criteria:

Patients with acute ischemic stroke who require endovascular intervention with whom mNIHSS score can be obtained
Patients with cerebral vasospasm suspiciousness with or without subarachnoid hemorrhage with whom mNIHSS score can be obtained.

Exclusion Criteria:

History of severe hepatic disease or severe renal disease (GFR<20).
Hemodynamic instability.
Pregnancy.
Known allergy to study drug.
Evidence or history of cardiac electrophysiology instability including uncontrolled hemodynamically unstable complex atrial/ventricular arrhythmia or conduction block at the time of evaluation with the exception of atrial fibrillation, and heart rate less than 60 or systolic blood pressure less than 90.
Respiratory compromise requiring intubation.
Any medical (including history of cardiac conduction block, major hepatic or renal disease) or laboratory abnormality that may increase the risk associated with the trial participation or drug administration or may interfere with interpretation of trial results.
Intervention: Oxymetazoline
Trial phase: Phase 4
ATC code: D11AX27 | R01AA05 | R01AB07 | S01GA04
SMILES: Cc1cc(C(C)(C)C)c(O)c(C)c1CC1=NCCN1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 25
Group description: 0.05% oxymetazoline nasal sprays 2 sprays in each nostril twice daily

oxymetazoline: 0.05% Oxymetazoline nasal sprays were commercially available.
Eligibility criteria:
Inclusion Criteria:

Patient 18 years of age or greater
Diagnosis with allergic or nonallergic rhinitis with persistent nasal obstruction
Being treated with intranasal steroid and oral antihistamine

Exclusion Criteria:

Underlying disease of hypertension
Use oral or nasal decongestant 7 days prior to entering the study
Nasal polyp or significant deviated nasal septum
Respiratory tract infection 14 days prior to entering the study